ScreenDx identifies previously underdetected interstitial lung disease in COPDGene scans
Source check: Source checked. Not independent scientific confirmation.
Finding: A retrospective COPDGene analysis used a learned CT model to detect cases subsequently relabeled as clinically significant interstitial lung disease. The original abstract reports 84.8% sensitivity and 98.0% specificity in a deliberately sampled cohort. This does not establish prospective screening benefit.
Technology: ScreenDx deep learning CT classifier
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A learned ScreenDx model evaluates CT features compatible with ILD; this is a retrospective test against subsequently assigned clinical reference labels.
- Test and result
- The source selected patients subsequently relabeled by COPDGene investigators as ILD-positive and sampled COPD/control negatives to target approximately 1–2% ILD prevalence. At a previously selected threshold, abstract-reported sensitivity was 84.8%(95% CI 68.1–94.9%) and specificity 98.0%(97.3–98.5%).
- Limitation / still unknown
- This review had the complete original abstract and primary bibliographic metadata, not full Methods. Exact sample counts, details of clinical adjudication, model-development overlap and threshold-lock timing were not authenticated. Positives had already been relabeled by investigators; these are not newly confirmed diagnoses made in a prospective AI screening program. Deliberate negative sampling limits prevalence-dependent interpretation. No improved patient outcomes or causal clinical benefit is established. The original journal history gives online publication November 26,2025, while PubMed records November 27; the represented date follows the original publisher.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41314436/ · https://www.resmedjournal.com/article/S0954-6111%2825%2900608-0/abstract
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 21 Nov 2026. Review scope: Complete original PubMed/EuropePMC abstract plus indexed original journal abstract and original publisher publication history actually read; full Methods unavailable (journal403)..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.